USFDA accepts biosimilar application of Zydus and German firm for Keytruda

The US Food and Drug Administration (FDA) has accepted a biosimilar application for Keytruda, a cancer drug, from Zydus Cadila and a German firm.

This is a significant development in the field of cancer treatment, as biosimilars are less expensive alternatives to branded biological drugs.